MICHAEL RASMUSSEN: Open Payments
NPI 1487056339 · GARLAND, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$209 in 9 payments from 7 companies in 2025. Trend: 2023 $219 · 2024 $293 · 2025 $209
Food & beverage: $209
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $35 |
| Seqirus USA Inc | 1 | $23 |
| ABBVIE INC. | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Novo Nordisk Inc | 1 | $15 |
Products named: JARDIANCE, CAPLYTA, Fluad, VRAYLAR, ZORYVE, Dexcom G6 Transmitter, Ozempic.
Industry payments across UT — which companies pay providers there.
